Current possibilities of nebulizer therapy in the treatment of respiratory pathology in children
- Authors: Shakhnazarova M.D1,2, Geppe N.A1, Ozerskaya I.V1, Chepurnaya M.M3, Shatalina S.I1,2
-
Affiliations:
- Sechenov University
- N.F. Filatov Clinical Institute of Children Health
- Rostov State Medical University
- Issue: Vol 28, No 1 (2021)
- Pages: 20-26
- Section: Articles
- URL: https://journals.eco-vector.com/2073-4034/article/view/313053
- DOI: https://doi.org/10.18565/pharmateca.2021.1.20-26
- ID: 313053
Cite item
Abstract
Full Text
About the authors
M. D Shakhnazarova
Sechenov University; N.F. Filatov Clinical Institute of Children Health
Email: marinashakh@mail.iu
Cand. Sci. (Med.), Associate Professor, Department of Childhood Diseases
N. A Geppe
Sechenov University
I. V Ozerskaya
Sechenov University
M. M Chepurnaya
Rostov State Medical University
S. I Shatalina
Sechenov University; N.F. Filatov Clinical Institute of Children Health
References
- Stein S.W, Thiel C.G. The History of Therapeutic Aerosols: A Chronological Review. J Aerosol Med Pulm Drug Deliv. 2017;30(1):20-41. doi: 10.1089/jamp.2016.1297.
- Boe J., Dennis J.H., O'Drisscol B.R. Europian Respiratory Society Guidelines on the use of Nebulizers. ERJ. 2001;18(1):228-42. doi: 10.1183/09031936.01.00220001.
- Gillen M, Forte P, Svensson J.O., et al. Effect of a spacer on total systemic and lung bioavailability in healthy volunteers and in vitro performance of the Symbicort® (budesonide/formoterol) pressurized metered dose inhaler Pulm Pharmacol Ther. 2018;52:7-17. Doi: 10.1016/j. pupt.2018.08.001.
- Pirozynski M., Sosnowski T.R. Inhalation devices: from basic science to practical use, innovative vs generic products. Exp Opin Drug Deliv. 2016;13(11):1559-71. doi: 10.1080/17425247.2016.1198774.
- Roy A., Pleasants R.A., Hess D.R. Aerosol Delivery Devices for Obstructive Lung Diseases. Respir Care. 2018;63(6):708-33. Doi: 10.4187/ respcare.06290.
- Белоцерковская Ю.Г Возможности клинического применения современных небулайзеров. Медицинский совет. 2020;(17):50-5.
- Ari A., Fink J.B. Recent advances in aerosoldevices for the delivery of inhaled medications. Exp Opin Drug Deliv. 2020;17(2):133-44. doi: 10.1080/17425247.2020.1712356.
- Edge R., Butcher R. Vibrating Mesh Nebulizers for Patients with Respiratory Conditions: Clinical Effectiveness, Cost-Effectiveness, and Guidelines. Ottawa: CADTH, 2019. 20 p.
- Kaiser S.V, Huynh T., et al. Preventing Exacerbations in Preschoolers With Recurrent Wheeze: A Metaanalysis. Pediatr. 2016;137(6):e20154496. doi: 10.1542/peds.2015-4496.
- Геппе Н.А. Ингаляционная небулайзерная терапия заболеваний респираторной системы Практическое руководство для врачей М., 2008. 82 с. [Geppe N.A. Inhalation nebulizer therapy of diseases of the respiratory system. Practical guide for doctors. M., 2008. 82 p. (In Russ.)].
- Геппе Н.А., Колосова Н.Г, Зайцева О.В., Захарова И.Н. и др. Диагностика и терапия бронхиальной астмы у детей дошкольного возраста. Место небулизированных ИГКС в терапии бронхиальной астмы и крупа. (Консенсус по результатам совета экспертов Педиатрического респираторного общества). Российский вестник перинатологии и педиатрии. 2018;63:(3):124-32.
- Global Strategy for Asthma Management and Prevention. Global Initiative for Asthma (GINA). Updated 2020. URL: http://www.ginasthma.org.
- Национальная программа «Бронхиальная астма у детей. Стратегия лечения и профилактика». М., 2017. 160 с. [National program "Bronchial asthma in children. Treatment strategy and prevention". M., 2017. 160 p. (In Russ.)].
- Yoshihara S., Tsubaki T., Ikeda M., et al. The efficacy and safety of fluticasone/salmeterol compared to fluticasone in children younger than four years of age. Pediatr Allergy Immunol. 2019;30(2):195-203. doi: 10.1111/pai.13010.
- Shui-Juan Zhang, Juan-Xia Jiang, Qian-Qian Ren, et al. Ambroxol inhalation ameliorates LPS-induced airway inflammation and mucus secretion through the extracellular signal-regulated kinase 1/2 signaling pathway. Eur J Pharmacol. 2016;775:138-48.
- Ozawa K., Tamura A., Ikeda K., et al. Videomicroscopy for analysis of molecular dynamics in cells. J Pharm Biomed Anal. 1997;15(9-10):1483-88. doi: 10.1016/s0731-7085(97)00036-8.
- Suarez-Castanon C., Modrono-Riano G., Lopez-Vilar P, et al. Use of cold and cough medications prescribed in Primary Care clinics for children less than 14 years. Anales de Pediatri a: Publicacion Oficial de la Asociacio n Espan ola de Pediatri a (A.E.P). 2016;84(1):10-7. Doi: 10.1016/j. anpedi.2015.02.022.
- Овчаренко Л.С., Вертегел А.А., Андриенко Т. Гидр. Ингаляционные формы амброксола в терапии секреторно-эвакуаторных нарушений респираторного тракта при острых бронхитах у детей. Здоровье ребенка. 2014;3(54):25-8
- Мизерницкий Ю.Л. Клиническая эффективность муколитической терапии амброксолом у детей. Практическая пульмонология. 2019;2:84-6
- Kanie S., Yokohira M., Yamakawa K., et al. Suppressive effects of the expectorant drug ambroxol hydrochloride on quartz-induced lung inflammation in F344 rats. J Toxicol Pathol. 2017;30(2):153-59. doi: 10.1293/tox.2016 0050
- Европейские медицинские агентства. Пересмотренный отчет об оценке: лекарственные средства, содержащие амброксол и бромгексин. 2015. [European medical agencies. Revised Evaluation Report: Medicines Containing Ambroxol and Bromhexine. 2015. (In Russ.)]. URL: https://www.ema.europa.eu/en/documents/ referral/ambroxol-bromhexine-article-31-referral-pracassessment-report_ en.pdf
- Paleari D., Rossi G.A., et al. Ambroxol: a multifaceted molecule with additional therapeutic potentials in respiratory disorders of childhood. Published on-line: 25 Oct 2011. P 1203-121. Doi: https://doi.org/10.1517/17460441.2011.6296 46. (date of access: 10.01.2021)
- Deretic V, Timmins G.S. Enhancement of lung levels of antibiotics by ambroxol and bromhexine. Exp Opin Drug Metab Toxicol. 2019;15(3):213 18. doi: 10.1080/17425255.2019.1578748
- Yang Z., et al. Effects and mechanisms of ambroxol inhalation (Mucosolvan®) in the treatment of neonatal pneumonia. Pharmazie. 2017;72(10):604-7. Doi: 10.1691/ ph.2017.7541.
- Li F., Yu J., Yang H., et al. Effects of ambroxol on alginate of mature Pseudomonas aeruginosa biofilms. Curr Microbiol. 2008;57(1):1-7. doi: 10.1007/s00284-008-9142-8.
- Du X., Zhao C., Liu S., Su S. Value of ambroxol in the treatment of asthmatic bronchitis. Pak J. Med Sci. 2020;36(3):501-4. Doi: 10.12669/ pjms.36.3.1607.
- Зайцев А.А. Современный взгляд на фармакотерапию кашля. Практическая пульмонология. 2018;3:88-94.
- Bradfute S.B., Ye C., Clarke E.C. Ambroxol and Ciprofloxacin Show Activity Against SARS- CoV2 in Vero E6 Cells at Clinically-Relevant Concentrations. bioRxiv preprint. Doi: https://doi. org/10.1101/2020.08.11.245100.
- Olaleye O.A., Kaur M., Onyenaka C.C. Ambroxol Hydrochloride Inhibits the Interaction between Severe Acute Respiratory Syndrome Coronavirus 2 Spike Protein's Receptor Binding Domain and Recombinant Human ACE2. Preprint. Doi: https:// doi.org/10.1101/2020.09.13.295691 (date of access: 12.01.2021).
- Данные инструкций по медицинскому применению препаратов, содержащих амброксол. ГРЛС (Электронный ресурс). [Data of instructions for medical use of preparations containing ambroxol. State register of medicines (Electronic resource). (In Russ.)]. URL: https://grls.rosminzdrav.ru/grls. aspx (дата доступа/date of access: 12.01.2021).
- Yang C., Montgomery M. Dornase alfa for cystic fibrosis (Review). Cochrane Database Syst Rev. 2018:9(issue 9):CD001127. doi: 10.1002/14651858.CD001127.pub4.
- Lee S.H., Heng D., Teo J.W.P., et al. inhaled mucoactive particles with tailored architecture for enhanced aerodynamicity, stability and efficacy intern J. Pharmaceut. 2019;572:118740. doi: 10.1016/j.ijpharm.2019.118740.
- Thomas P., Baldwin C., Bissett B., et al. Physiotherapy management for COViD-19 in the acute hospital setting: clinical practice recommendations. J. Physiother. 2020;66(2):73-82. Doi: 10.1016/j. jphys.2020.03.011.